Search 

Prolog Ventures is a venture capital firm based out of St. Louis Missouri that was founded in 2001. The firm is currently making investments out of its vintage 2013 4th fund of approximately $100 million. The firm is looking to make equity investments in companies ranging from $500,000 to $3 million. The firm will invest in companies across the United States and plans to make approximately 3-4 investments over the next 6-9 months.

River Cities Capital Fund is a private equity firm founded in 1994 and based in Cincinnati, Ohio. The firm manages approximately $500 million under management and is currently investing out of its 2014 vintage $200 fund. The firm looks to make investments of $5-$15 million initially up to $20 million over the investments lifetime. The firm is willing to invest throughout the United States and is looking to make approximately 4-6 equity investments over the next 6 to 9 months.

RiverVest Venture Partners is a venture capital firm that was founded in 2000 and is based in St. Louis, Missouri with additional office in Cleveland, Ohio. The firm currently has managed over $208 million of total assets. RiverVest has raised two investment funds with total committed capital of $165 million since inception. The recent fund closed at $75 million. RiverVest typically makes equity investments into global companies, and has no specific geographic preferences. The firm will consider making investments at all the stages, and focuses on investments in seed, early-stage and select later-stage companies. The typical investment size is around $6 million, though the firm can invest more or less, depending on the opportunity. 

RiverVest is extremely opportunistic when it comes to investments in the life sciences space; with that being said RiverVests specified sectors and sub sectors of interest may or may not be an area in which RiverVest is currently looking to allocate capital to. The firm invests in companies in the biotech therapeutics and diagnostics, as well the medical technology space. 

Some of the firms investments have included companies developing biotech therapeutics and diagnostics targeting diseases of the blood and blood forming organs, neoplasms, cancer, and oncology, skin and subcutaneous tissue, cardiovascular diseases, diseases of the ear, and infectious diseases. The firm has also invested in companies developing anti-body based therapeutics. The firm has also invested in firms developing medical technologies such as therapeutic radiation devices, active implantable devices, non active implantable devices, hospital hardware, and imaging devices.

Sanus Asia is a Singapore based advisory firm providing investment and transaction-related services across Asia with a focus on Healthcare and Life Sciences.

We work with investors and high potential companies to assist growth/development across Asia through capital raising and strategic/operational support.

We seek to identify high potential US/European Medtech and Digital Health companies with near-term commercialisation potential in Asia.

Will also consider earlier stage investments as a principal Angel investor if there is a strong Asian angle to the technology/business model.

Seroba Kernel is a venture capital firm based in Dublin, Ireland, with representatives in the United Kingdom. The firm has approximately €100M AUM and focuses solely on the life sciences. The firm has 2 funds and plans to raise a third fund in the near future. The firm typically allocates between €5-7M of equity over the life of the investment. The firm primarily invests in companies that are based in Ireland and Europe. Exceptional opportunities in North America will also be considered. The firm is actively seeking new investment opportunities.

Sofia Angel Group is a group of angel investors based in Minneapolis, Minnesota. The group solely focuses on investing in women-led businesses where women are the founders, or women are on the senior management team. Sofia Angel Group does not have a specific timeframe to make an investment, however would make an allocation by the end of 2013 if a compelling opportunity is identified. The group typically invests around $100,000 per company, however has the ability to invest up to $3 million through co-investments from the group’s members.